Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.71 |
| ▸ | MAPK13 | O15264 | 7/20 | 0.52 |
| ▸ | MAPK12 | P53778 | 7/20 | 0.52 |
| ▸ | MAPK11 | Q15759 | 7/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.52 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.49 |
| ▸ | NOS2 | P35228 | 1/20 | 0.48 |
| ▸ | FADS1 | O60427 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4434910 | 0.88 | RECQL (0.53) | RECQLMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL9540049 | 0.86 | RECQL (0.79) | RECQLNOS2FADS1ALDH1A1KDM4E | |
| SCHEMBL6940121 | 0.85 | RECQL (0.58) | RECQLMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL4437961 | 0.84 | MAPK13 (0.55) | RECQLMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL8398995 | 0.83 | KCNMA1 (0.60) | RECQLMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL13955949 | 0.83 | MAPT (0.57) | RECQLMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL29516764 | 0.83 | RECQL (1.00) | RECQLMAPK14FADS1ALDH1A1KDM4E | |
| SCHEMBL333313 | 0.83 | RECQL (1.00) | RECQLMAPK14FADS1ALDH1A1KDM4E | |
| SCHEMBL27696663 | 0.82 | RECQL (0.56) | RECQLMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL538169 | 0.82 | GAA (0.59) | RECQLMAPK13MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083906-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | MILLENNIUM PHARM INC (US) | 2024-03-14 | — | — | US | disclosed |
| US-20220041605-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | MILLENNIUM PHARMACEUTICALS, INC. | 2022-02-10 | — | — | US | disclosed |
| US-11014928-B2 | Compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200247810-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | MILLENNIUM PHARMACEUTICALS, INC. | 2020-08-06 | — | — | US | disclosed |
| US-10414770-B2 | Compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-20180134716-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | MILLENNIUM PHARMACEUTICALS, INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180134714-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2018-05-17 | — | — | US | disclosed |
| US-9765078-B2 | Compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| EP-2719698-B1 | Methods for preparing aurora kinase inhibitors | MILLENNIUM PHARM INC (US) | 2016-10-05 | — | — | EP | disclosed |
| EP-2746285-B1 | Process for the preparation of aurora kinase inhibitors | MILLENNIUM PHARM INC (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-1905773-B1 | Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase | MILLENNIUM PHARM INC (US) | 2012-07-18 | — | — | EP | disclosed |
| EP-2261226-A1 | Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-12-15 | — | — | EP | disclosed |
| US-20090299060-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-7572784-B2 | Compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| EP-1905773-A2 | Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-04-02 | — | — | EP | disclosed |
| US-20070185087-A1 | Compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| CN-101014603-A | Compounds and methods for inhibiting mitosis by inhibiting aurora kinase | MILLENNIUM PHARM INC (US) | 2007-08-08 | — | — | CN | disclosed |
| EP-1771450-A2 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION BY INHIBITION OF AURORA KINASE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-04-11 | — | — | EP | disclosed |
| WO-2005111039-A2 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION BY INHIBITION OF AURORA KINASE | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256102-A1 | Compounds and methods for inhibiting mitotic progression | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247810-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | AURKC, AURKA, AURKB | RECQL 414/4885MAPK13 728/4885MAPK12 625/4885 |
| US-20050256102-A1 | Compounds and methods for inhibiting mitotic progression | AURKC, AURKA, AURKB | RECQL 414/4885MAPK13 728/4885MAPK12 625/4885 |
| US-20070185087-A1 | Compounds and methods for inhibiting mitotic progression | AURKC, AURKA, AURKB | RECQL 414/4885MAPK13 728/4885MAPK12 625/4885 |
| US-10414770-B2 | Compounds and methods for inhibiting mitotic progression | AURKC, AURKA, AURKB | RECQL 414/4885MAPK13 728/4885MAPK12 625/4885 |
| US-20180134716-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | AURKC, AURKA, AURKB | RECQL 414/4885MAPK13 728/4885MAPK12 625/4885 |
| US-11014928-B2 | Compounds and methods for inhibiting mitotic progression | AURKC, AURKA, AURKB | RECQL 414/4885MAPK13 728/4885MAPK12 625/4885 |
| US-20090299060-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | AURKC, AURKA, AURKB | RECQL 414/4885MAPK13 728/4885MAPK12 625/4885 |
| US-20180134714-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, NR2E3, LRAT | RECQL 359/4885MAPK13 4498/4885MAPK12 4397/4885 |
| US-20220041605-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | AURKC, AURKA, AURKB | RECQL 414/4885MAPK13 728/4885MAPK12 625/4885 |
| US-20240083906-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | AURKC, AURKA, AURKB | RECQL 414/4885MAPK13 728/4885MAPK12 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.